OABI · OmniAb, Inc.

The thesis

OmniAb's shares need partner milestone payments to repeat and lift 2026 revenue guidance above $36 million. The 6 October 2026 Investor and Analyst Day added a small new product forecast and left that guidance unchanged, and the shares closed lower. The third-quarter report, expected around 5 November 2026, is the next test.

The shares closed at $4.35 on 6 October 2026, down from $4.92 on 5 October 2026, in adjusted daily closes. The 6 October 2026 close is 13.7% below the $5.04 52-week high and 94.2% above its level three months earlier. The 14-day relative strength index (RSI) fell to 50.0 from 69.9 the session before.

At the Analyst Day, OmniAb guided 2026 revenue from its xPloration antibody-screening platform to $2–3 million. It expects that figure to double in 2027 and again in 2028. It also said as many as 19 clinical trials of OmniAb-derived drugs could reach primary completion in the rest of 2026 and in 2027 (OmniAb release via Stock Titan, 6 October 2026). The release gave no figure for contracted milestones and did not restate 2026 revenue or cash guidance.

The narrative is maturing: the story is well known, and the shares closed lower on the day the company laid out its multi-year outlook. One quarter of large milestone revenue is too small a sample to set a run-rate, so this note does not project one.

Bullish and bearish views on OmniAb, Inc.

The bull case on OmniAb, Inc. (OABI), in brief: Milestones already show up in revenue. The bear case: The Analyst Day drew selling.

Bull case

• Milestones already show up in revenue. OmniAb reported second-quarter 2026 revenue of $13.4 million on 6 August 2026, of which $9.515 million came from licenses and milestones. The same day it raised full-year revenue guidance to $32–36 million from $28–33 million (Q2 release).
• The third-quarter bar is low. OmniAb reported third-quarter 2025 revenue of $2.2 million on 4 November 2025 (Business Wire). FXEmpire listed a five-analyst consensus of $3.50 million of third-quarter 2026 revenue and a loss of $0.12 per share as of 6 October 2026.
• A wide partner book with trial readouts ahead. At 30 June 2026, OmniAb counted 110 active partners, 425 active programs and 34 OmniAb-derived programs in clinical development or on the market (Q2 release). The company said on 6 October 2026 that up to 19 partner trials could reach primary completion through 2027, and clinical steps can trigger milestone payments.
• A second revenue line is now on general sale. From October 2026, xPloration is available to all customers rather than only through the Partner Access Program launched in 2025. OmniAb puts the addressable market at more than $500 million (6 October 2026 release).
• Licensing lifted the cash outlook. On 17 August 2026, OmniAb raised expected year-end 2026 cash to $49–53 million from $37–41 million, citing technology licensing (OmniAb). The same day it announced an ion-channel collaboration with Eli Lilly carrying up to $370 million in contingent milestones plus tiered royalties.
• One sell-side target sits far above the price. H.C. Wainwright reiterated a Buy rating and an $11 target on 17 August 2026, per Benzinga's analyst log.

Bear case

• The Analyst Day drew selling. The shares closed at $4.35 on 6 October 2026 against $4.92 the prior session, after an event that carried no revenue or cash guidance change.
• xPloration is small against the total. The $2–3 million 2026 xPloration forecast compares with $32–36 million of total 2026 revenue guidance, so milestones still drive the year.
• Royalties remain a small line. Second-quarter 2026 royalty revenue was $266,000, against $9.515 million from licenses and milestones (Q2 release, 6 August 2026).
• The company still loses money. The second-quarter 2026 net loss was $5.9 million, or $0.05 per share. Full-year cost and operating expense guidance of $84–88 million exceeds the $32–36 million revenue outlook (Q2 release).
• Milestone timing sits with partners. OmniAb runs no trials of its own, and the 19 trial completions cited on 6 October 2026 are an upper bound ("as many as") on events partners control.

Price setup

The 6 October 2026 close of $4.35 sits between two reference points. Above is the $5.04 52-week high. Below is the 11 September 2026 close of $4.07, where the late-September advance began. A daily close below $4.07 would erase that advance.

The RSI reset to 50.0 on 6 October 2026 from 69.9 a session earlier, so the overbought reading of early October has cleared. The three-month gain of 94.2% still leaves the shares far above their July level. The main crowding marker now is the calendar: third-quarter results fall inside the next 30 days, and the shares have reacted sharply to company events.

Catalysts, next 30 days

• ~5 November 2026, est. Third-quarter 2026 results. Earnings Whispers lists 5 November 2026 after the close; OmniAb has not confirmed a date. In 2025 the company announced its third-quarter date on 14 October 2025 for a 4 November 2025 report. The report tests whether 2026 revenue guidance moves above $36 million, against a $3.50 million revenue consensus.

Elapsed catalysts

• Rest of 2026, undated — Partner trial completions. Up to 19 OmniAb-derived trials could reach primary completion through 2027, per the 6 October 2026 release. Each disclosed completion or advance is a possible milestone trigger. (passed 6d ago)

What would change the view

The case breaks if third-quarter results leave full-year 2026 revenue guidance at or below $36 million. That would mean the second-quarter milestones did not repeat. An equity offering or at-the-market sales disclosed in a filing would also weaken it, given the $84–88 million expense guidance. On price, a daily close below $4.07, the 11 September 2026 close, would mark the late-September advance as fully reversed.

The case strengthens if OmniAb raises revenue guidance above $36 million, announces a new licensing deal of the size of the 17 August 2026 Eli Lilly collaboration, or reports early xPloration sales that track its $2–3 million 2026 forecast. A close above the $5.04 52-week high would show buyers returning after the Analyst Day decline.

What it trades with

The shares move mostly on OmniAb's own events. The three-month gain spans the 6 August 2026 second-quarter results and the 17 August 2026 guidance raise, and the sharpest recent drop came on the 6 October 2026 Analyst Day. As a platform licensed to drug developers, OmniAb's deal flow tracks partner research budgets and clinical progress, so a pullback in biotech funding would likely slow new licenses; a quarter with no new partner agreements would confirm that link. Milestone revenue ties the company to large partners such as Eli Lilly, but each payment depends on a single program's timing.